Belzutifan (DrugBank ID: DB14980)
Brand name: Jemperli (US) / Roche® 019 (other markets)
1. What is Belzutifan?
Belzutifan is a small‑molecule, oral inhibitor of hypoxia‑inducible factor‑2α (HIF‑2α).
It is the first clinically approved drug that directly targets HIF‑2α, a transcription factor that is over‑activated in a range of tumors driven by hypoxia and vascular endothelial growth factor (VEGF) signaling.
2. Indications (as of the last update)
| Indication |
Market |
Approval Year |
| Von Hippel–Lindau (VHL) disease–associated renal cell carcinoma (RCC) |
US, EU, Canada |
2023 (FDA) |
| Clear‑cell renal cell carcinoma (ccRCC) – patients who have progressed after at least one prior VEGF‑targeted therapy |
US, EU, Canada |
2023 (FDA) |
| Pancreatic neuroendocrine tumors (pNETs) – advanced or metastatic disease |
US, EU, Canada |
2023 (FDA) |
Note: The drug is under investigation for other tumor types (e.g., hepatocellular carcinoma, prostate cancer) in clinical trials.
3. Mechanism of Action
| Step |
Detail |
| Target |
HIF‑2α protein (part of the HIF‑1/2α/β heterodimer complex). |
| Binding site |
Intracellular, pocket that stabilizes HIF‑2α’s interaction with the β‑subunit; prevents DNA binding. |
| Effect |
↓ Transcription of genes involved in angiogenesis (VEGFA, PDGFA), erythropoiesis (EPO), glycolysis, and cell proliferation. |
| Outcome |
↓ Tumor vascularization, ↓ tumor growth, ↓ metastatic potential. |
4. Pharmacokinetics
| Parameter |
Typical Value (oral 120 mg QD) |
| Bioavailability |
~70% (Cmax 1‑2 h post‑dose). |
| Cmax |
100–150 ng/mL (varies with food). |
| Half‑life |
~8–12 h (steady state in 5–7 days). |
| Metabolism |
Primarily CYP3A4‑mediated; minor contribution from CYP2C19. |
| Excretion |
Feces (≈70 %) and urine (≈20 %). |
| Special Populations |
Dose adjustments not required for mild‑moderate hepatic impairment; caution in severe hepatic disease. |
5. Dosing & Administration
- Adult dose: 120 mg orally once daily, with or without food.
- Maintenance: 120 mg daily after an initial 4‑week lead‑in (for some indications).
- Adherence: Patients should take at the same time each day to maintain trough levels.
6. Major Adverse Reactions
| Class |
Common / Serious |
| Gastrointestinal |
Nausea, vomiting, diarrhea, constipation. |
| Hematologic |
Thrombocytopenia, anemia, leukopenia. |
| Metabolic |
Hyperglycemia, hypophosphatemia. |
| Other |
Fatigue, headache, dysgeusia (taste changes), vision changes. |
Close monitoring of complete blood count, liver function tests, and electrolytes is recommended.
7. Contraindications & Precautions
- Contraindications: Known hypersensitivity to belzutifan or any excipients.
- Precautions:
- Pregnancy: Category X – avoid.
- Breastfeeding: Excretion in milk; contraindicated.
- Concurrent use: Avoid strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin).
- Cardiovascular: Monitor blood pressure; HIF‑2α inhibition can alter vascular tone.
8. Drug–Drug Interactions
| Concomitant Drug |
Interaction |
| CYP3A4 inhibitors (ketoconazole, clarithromycin) |
↑ Belzutifan exposure → ↑ toxicity. |
| CYP3A4 inducers (rifampin, carbamazepine) |
↓ Belzutifan levels → ↓ efficacy. |
| Warfarin |
Potential ↑ bleeding risk; monitor INR. |
| Diuretics (e.g., furosemide) |
May potentiate hypophosphatemia. |
9. Clinical Trial Highlights
| Phase |
Study |
Population |
Outcome |
| Phase I |
NCT02663515 |
Healthy volunteers |
MTD 120 mg QD; safety profile as above. |
| Phase II |
NCT03315409 |
VHL‑associated RCC |
60‑day objective response rate ~20 %. |
| Phase III |
NCT03935117 |
Advanced ccRCC after VEGF therapy |
12‑month PFS 9.3 months vs. 3.8 months placebo; OS improved. |
| Phase III (pNET) |
NCT03848253 |
Advanced pNET |
ORR 18%; disease control rate 70%. |
10. How to Use DrugBank for Further Information
- Navigate to the DrugBank website (https://go.drugbank.com/).
- Search for “Belzutifan” or its DrugBank ID “DB14980”.
- Explore sections:
- Pharmacology – detailed mechanism.
- Clinical Trials – active studies.
- Adverse Reactions – patient‑reported outcomes.
- Drug Interactions – full list and strength.
11. Quick Reference (One‑Pager)
| Feature |
Detail |
| Drug |
Belzutifan (Jemperli) |
| Target |
HIF‑2α |
| Dose |
120 mg PO QD |
| Approval |
FDA 2023 (RCC, pNET) |
| Key Adverse |
Nausea, thrombocytopenia, hyperglycemia |
| Main Interaction |
CYP3A4 modulators |
| PK |
T½ ≈10 h, Cmax ~1–2 h |
| Special |
Avoid in pregnancy & lactation |
Bottom Line
Belzutifan represents a breakthrough in targeted oncology, offering a new therapeutic option for patients whose tumors depend on HIF‑2α signaling. Its oral formulation, manageable safety profile, and clear mechanism make it a valuable tool in the modern cancer armamentarium. For the latest updates (e.g., expanded indications, new trial data), always consult the DrugBank entry or peer‑reviewed literature.